What Supreme Court’s Myriad decision means for biopharma companies

On 13 June 2013, the US Supreme Court ruled that certain patent claims owned by Myriad Genetics, the US biotech company that holds the patents covering a test for breast-cancer-related genes (BRCA1 and BRCA2), are invalid as products of nature.

The court held that a naturally occurring DNA segment is ‘a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring’.

Key to the decision was the finding that isolating DNA from the human genome does not change the chemical structure, nor does it alter the genetic information encoded in the BRCA1 and BRCA2 genes. In other words, the sequence and coding information is inherent in that gene, isolated or not…

If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.

Briefings from DLA Piper

View more briefings from DLA Piper

Analysis from The Lawyer

View more analysis from The Lawyer

Overview

3 Noble Street
London
EC2V 7EE
UK
http://www.dlapiper.com

Turnover (£m): 1,539.00
No. of Lawyers: 4,374